TG Therapeutics wins VA contract for MS drug
NEW YORK – TG Therapeutics, Inc. (NASDAQ: NASDAQ:) has secured a national contract with the Department of Veterans Affairs (VA) to include its drug BRIUMVI® (ublituximab-xiiy) on the VA National Formulary as the preferred Anti-CD20 Antibody treatment for veterans with relapsing forms of multiple sclerosis (RMS). This contract, effective from …